|Bid||0.00 x 3100|
|Ask||0.00 x 800|
|Day's Range||14.34 - 14.51|
|52 Week Range||13.92 - 15.39|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.00|
|Expense Ratio (net)||0.68%|
Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...
The biotechnology space is one of the most exciting and innovative corners of the broader healthcare sector. Some exchange traded funds (ETFs) reflect that innovation including a new fund Global X. The ...
Since the completion of the National Institutes of Health and Department of Energy-funded Human Genome Project in 2003, genomics has been one of the most compelling areas of the biotechnology universe. ...
Global X debuted a new fund on Tuesday that's among the first ETFs to explicitly track the genomics market with targeted, pure play exposure. The Global X Genomics & Biotechnology ETF (GNOM) becomes Global X's 13th fund in its Thematic Growth suite. The new ETF stands to benefit from advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
NEW YORK , April 9, 2019 /PRNewswire/ -- Global X ETFs, the New York -based provider of exchange-traded funds, announced today the launch of the 13 th fund in its Thematic Growth suite, the Global X Genomics ...